|Bid||118.71 x 800|
|Ask||118.81 x 1200|
|Day's Range||118.21 - 119.03|
|52 Week Range||90.64 - 120.00|
|Beta (3Y Monthly)||0.33|
|PE Ratio (TTM)||38.36|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||1.48 (1.30%)|
|1y Target Est||109.29|
Today we are going to look at ResMed Inc. (NYSE:RMD) to see whether it might be an attractive investment prospect. In...
ResMed (RMD) (RMD.AX) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society.
ResMed Inc NYSE:RMDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for RMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding RMD totaled $6.23 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Measuring ResMed Inc.'s (NYSE:RMD) track record of past performance is an insightful exercise for investors. It...
ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general manager for India and South Asia.
ResMed today announced that Rob Douglas, president and chief operating officer, will participate in a fireside chat discussion at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019, beginning at approximately 10:00 a.m.
ResMed today announced that Mick Farrell, chief executive officer, will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019, beginning at approximately 8:40 a.m.
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.
.@ResMed study finds #CPAP adherence improved by remote monitoring, self-monitoring across 3 countries
Age, gender, and disease severity all impact long-term #CPAP adherence more than previously thought, according to a million-patient study shown at #ATS2019 #sleepapnea
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital SaaS solutions, today announced it has elected experienced business executive Jan De Witte to its board of directors. Mr. De Witte was appointed during ResMed’s regularly scheduled board meeting on May 16, 2019, to fill a newly created directorship, effective immediately.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Brightree® today announced plans for its Home Health and Hospice customers to access more than 50,000 provider locations and health systems nationwide via the CommonWell Health Alliance, a nonprofit national trade association of health IT companies, and through CommonWell to Carequality, a national, consensus-built common interoperability framework. This represents an important step forward in bridging the gap between out-of-hospital care providers and the broader care ecosystem, solving for when providers lose visibility into their patients’ care when they enter a post-acute care setting.
ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.
ResMed (RMD) delivered earnings and revenue surprises of 5.95% and -0.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had net income of 73 cents per share. Earnings, adjusted for amortization costs and pretax expenses, came to 89 cents per share. The results exceeded Wall Street expectations. ...
SAN DIEGO-- -- Year-over-year revenue grows 12%, gross margin improves 100 basis points, operating profit up 15% MatrixCare contributes positively to revenue, gross margin, and profit ResMed well-positioned for the future Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com ResMed Inc. , a world-leading connected health company, today announced ...
It’s time for the one-year update on a set of stocks that David Gardner picked to commemorate April the giraffe giving birth live on YouTube.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.